Eloralintide (10mg)

Eloralintide (LY3841136) is a long-acting, selective amylin receptor agonist — a synthetic compound that mimics amylin, the pancreatic hormone released alongside insulin after eating. Amylin tells the brain you are full, slows how quickly the stomach empties and helps steady post-meal blood sugar. Native amylin is cleared within minutes, so Eloralintide was engineered as a stable, once-weekly form that lets researchers study the amylin pathway over long time courses.

Both are long-acting amylin-class compounds, but they differ in receptor selectivity. Cagrilintide is a dual amylin and calcitonin receptor agonist (DACRA), engaging both receptor families. Eloralintide is designed to act selectively on the amylin receptor with minimal calcitonin receptor activity. Researchers use the pair to separate which effects come from amylin signalling alone and which depend on calcitonin receptor engagement, and to compare tolerability between the two profiles.

Semaglutide, Tirzepatide and Retatrutide all work through incretin receptors — GLP-1, and in the multi-agonists GIP and glucagon as well. Eloralintide works through a completely separate pathway: the amylin receptor. That makes it a complementary rather than competing mechanism, which is why it is being studied both as a standalone compound and in combination with Tirzepatide, where the amylin signal stacks on top of the incretin signal rather than amplifying it.

A 48-week Phase 2 study in 263 adults with obesity or overweight reported mean body weight reductions ranging from about 9.5% at the lowest dose to 20.1% at the highest, against 0.4% on placebo, with the majority of participants at higher doses reaching at least 10% reduction. Gastrointestinal side effects were mostly mild to moderate and, at lower doses, similar to placebo. Phase 3 monotherapy trials began in late 2025, and a separate Phase 2 program is examining Eloralintide combined with Tirzepatide.

Eloralintide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 8–12 weeks. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilized Eloralintide vials at -20°C, away from light and moisture. After reconstitution with BAC water, refrigerate at 2–8°C and use within 8–12 weeks. Do not freeze the reconstituted solution.

Eloralintide (10mg) will be available through Aussie Peptides with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia, reducing delays linked to international freight and customs processing. Batch-specific Certificate of Analysis access will be available in our CoA library.

Eloralintide (10mg) is currently available on pre-order at Aussie Peptides, with dispatch expected between 16 September 2026 and 18 September 2026. Eloralintide (10mg) is priced at $279.99 per vial at Aussie Peptides. All orders ship domestically within Australia, and batch CoAs are available in our CoA library.